Displaying 1621 - 1640 of 4377
1709006 Informal Interpretation
1709005 Informal Interpretation
1709004 Informal Interpretation
FTC Testifies before House Judiciary Subcommittee About the Competitive Effects of Occupational Licensing Restrictions
FTC and Justice Department Announce Guidance for Post-Hurricane Relief Efforts
Antitrust Enforcement in the Digital Age
Prepared Statement of the Federal Trade Commission on Competition and Occupational Licensure, Before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Judiciary Committee, United States House of Representatives
1709002 Informal Interpretation
FTC Announces Second Economic Liberty Public Roundtable
1709001 Informal Interpretation
Mars, Incorporated and VCA Inc.; Analysis To Aid Public Comment Proposed Consent Agreement
FTC Acting Chairman Maureen K. Ohlhausen Announces Selection of Ian R. Conner as an Acting Deputy Director of the Bureau of Competition
Grifols, S.A., and Talecris Biotherapeutics Holdings Corp., In the Matter of
The FTC required Grifols, S.A., a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. It resolves FTC charges that Grifols’ proposed acquisition of Talecris would be anticompetitive and would violate federal antitrust laws. As part of the settlement, Grifols will sell the Talecris fractionation facility in Melville, New York, and Grifols’ plasma collection centers in Mobile, Alabama, and Winston-Salem, North Carolina, to Kedrion S.p.A. Kedrion is a manufacturer of plasma-derived products in Europe and other markets, and will be a new entrant in the U.S. plasma-derived products industry. Grifols also will manufacture three plasma-derived products for Kedrion for several years under a manufacturing agreement. The FTC approved a final order on July 22, 2011.
Displaying 1621 - 1640 of 4377